Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats

https://doi.org/10.1016/0041-008X(87)90178-5Get rights and content

Abstract

Cisplatin neurotoxicity was studied in rats by using electrophysiological and functional tests. The drug was injected intraperitoneally two times a week (1 mg/kg) up to a cumulative dose of 19.0 mg/kg body wt. At this dose the H-reflex-related sensory nerve comduction velocity was reduced. After cessation of drug administration, the H-reflex-related sensory nerve conduction velocity slowly improved. The motor nerve conduction velocity remained unaffected throughout the intoxication period and concentric needle investigation showed no signs of denervation. In addition, the sensorimotor response to a noxious stimulus presented locally to the foot sole was not affected by the cisplatin treatment. It is concluded that measurement of H-reflex-related sensory nerve conduction velocity is a useful and accurate tool in the evaluation of cisplatin neurotoxicity in rats.

References (18)

There are more references available in the full text version of this article.

Cited by (68)

  • The role of DNA damage and repair in toxicity to postmitotic cells caused by cancer therapies

    2016, DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition
  • Cerebellum neurotransmission during postnatal development: [Pt(O,O'-acac)(γ-acac)(DMS)] vs cisplatin and neurotoxicity

    2015, International Journal of Developmental Neuroscience
    Citation Excerpt :

    The effects of cisplatin [cis-diamminedichloroplatinum(I)I] (cisPt), the most widely used drug in the chemotherapy of cancer (Brezden et al., 2000), in rodents is similar to that seen in patients. Several groups have studied the effects of cisPt on the peripheral nervous system of rats (De Koning et al., 1987; Holmes et al., 1998; Tomiwa et al., 1986) and mice (Carozzi et al., 2009). CisPt has been shown to be toxic to cell populations in culture (Bottone et al., 2008; Santin et al., 2011, 2013), to the developing CNS (Avella et al., 2006; Cerri et al., 2011; Piccolini et al., 2012; Pisu et al., 2004; review: Bernocchi et al., 2011).

  • Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy

    2013, Pharmacology Biochemistry and Behavior
    Citation Excerpt :

    On the contrary, the effects produced by cisplatin on thermal sensitivity remain controversial. Some studies have reported thermal hypoalgesia (Authier et al., 2003; Boyle et al., 1999) or hyperalgesia (Ta et al., 2009) whereas others have found no change (Hori et al., 2010; De Koning et al., 1987; Tredici et al., 1999; present results) in the responses to thermal stimulation following treatment with cisplatin. In humans, the heat pain threshold did not change in cisplatin-treated patients after 3, 6 or 9 cycles of chemotherapy (Attal et al., 2009).

  • The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies

    2011, DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications
  • Upregulations of P2X<inf>3</inf> and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats

    2010, Pain
    Citation Excerpt :

    In our cumulative-dose protocol (15 mg/kg), cisplatin treatment had no effect on motor performance in the rota-rod test. This finding is consistent with previous reports that the motor nerve conduction velocity remained electrophysiologically unaffected, while the sensory nerve conduction velocity was reduced [15]. A previous study reported that administrations of cisplatin (total dose 32 mg/kg) intraperitoneally in female Dark Agouti rats produced reductions in both rota-rod performance and gait disturbance [9].

View all citing articles on Scopus

Supported in part by a grant from the Koningin Wilhelmina Fonds.

View full text